NCT02739165View on ClinicalTrials.gov

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

December 31, 2018

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

ART-123

380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy

DRUG

Placebo

Placebo by intravenous drip infusion in addition to standard of care steroid therapy

Trial Locations (26)

Unknown

Nagoya

Seto

Kamogawa

Sakura

Kurume

Ōgaki

Himeji

Kobe

Naka

Yokohama

Sendai

Tenri

Kurashiki

Sakai

Sayama

Hamamatsu

Shimotsuke

Bunkyo

Minato

Ōta-ku

Shibuya City

Shinjuku

Chiba

Fukuoka

Kumamoto

Nagasaki

All Listed Sponsors

lead

Asahi Kasei Pharma Corporation

INDUSTRY

NCT02739165 - Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter